US6936280B1 - Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology - Google Patents

Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology Download PDF

Info

Publication number
US6936280B1
US6936280B1 US10/089,982 US8998202A US6936280B1 US 6936280 B1 US6936280 B1 US 6936280B1 US 8998202 A US8998202 A US 8998202A US 6936280 B1 US6936280 B1 US 6936280B1
Authority
US
United States
Prior art keywords
composition
mother
pearl
approximately
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/089,982
Other languages
English (en)
Inventor
Evelyne Lopez
Alfred Edouard Chemouni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEMOUNI, EDOUARD, LOPEZ, EVELYNE
Application granted granted Critical
Publication of US6936280B1 publication Critical patent/US6936280B1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/42—Colour properties
    • A61K2800/43—Pigments; Dyes
    • A61K2800/436—Interference pigments, e.g. Iridescent, Pearlescent

Definitions

  • the present invention relates to a method for preparing a composition comprising all the components of mother-of-pearl, at least one collagen and at least one proteoglycan, to the composition which can be obtained using this method and to the use of the latter both in the pharmaceutical domain and in the domain of cosmetics, in particular for combating the effects of aging of the skin and/or of superficial skin growths.
  • Mammals are protected from the outside environment by a barrier consisting of the skin, which is a highly structured tissue composed of several layers, but sensitive to attacks due to the variations in the extracorporeal environment. This situation is unique in the animal kingdom since fish and frogs secrete mucus, birds are covered with feathers, and submammalian and mammalian vertebrates, except current Hominidae, are covered with hair.
  • aging is a physiological phenomenon which results in particular in thinning of the skin and a loss of elasticity, leading in particular to the appearance of more or less deep wrinkles. Loosening or drying-out of the surface and anarchic pigmentation may also be observed.
  • the skin comprises three layers: the epidermis, the dermis and, deep down, the hypodermis.
  • the outermost protective envelope of the skin, the epidermis, which tightly covers the dermis, consists, at the surface, of the stratum corneum.
  • the stratum corneum is made of two layers: the stratum disjunctum at the surface, the particularity of which is desquamation, and the stratum compactum, the deepest, which plays the role of a barrier.
  • the epidermis which is easy to observe macroscopically since it is at the surface, has been the subject of many studies. Known responses are those caused by certain agents of the extracorporeal environment or those resulting from the application of active substances of diverse origins.
  • the cells of the epidermis result from the activity of the cells of the basal layer which lies on a basal membrane separating the epidermis from the dermis.
  • the dermis results from the biosynthetic activity of fibroblasts, which produce the constituents of the extracellular matrix.
  • the latter is made up of four major families of macromolecules: collagens, elastin, structural glycoproteins and proteoglycans.
  • the dermis has the ability to respond to the signals given out by the epidermis, which, in response, also sends signals to the epidermis.
  • exchanges exist between these various dermal and epidermal layers of the skin, which are intended to ensure cell renewal and the cohesion and moisturization of the outer layers.
  • mother-of-pearl has been used since the beginning of time in aesthetics and in conventional pharmacopeiae. Moreover, mother-of-pearl is known for its bone-regenerating properties.
  • mother-of-pearl, or conchiferous aragonite is a biogenic mineralized formation; it consists of an organic matrix of fibrous and nonfibrous substances representing approximately 1.7 to 2% of the total mass (Taylor et al, Bulletin of the British Museum (Natural history) Zoology. Suppl. 3125 pp.+29 Plates, 1969) and of calcium carbonate crystallized in orthorhombic form, named aragonite, combined with trace elements (sodium, magnesium, lanthanum, zinc, bromine, cesium, iron, manganese, chlorine, copper, potassium, calcium, strontium and sulfur).
  • the entire organic phase of mother-of-pearl is in the form of an organic matrix composed of fibrous proteins, consisting in particular of ancestral collagens lacking hydroxyproline and hydroxylysine, and of nonfibrous proteins.
  • Approximately 50% of the organic matrix of mother-of-pearl is water-soluble. The remaining 50% can only be obtained after decalcification.
  • the products of the prior art obtained by mixing a mother-of-pearl powder with a pulverulent, inert diluent or excipient, as described, for example, in application WO 97/23231, cause undesirable phenomena of skin irritation, due to the presence of the mother-of-pearl in the form of powder (in particular of its major component, aragonite or CaCO 3 ). It is therefore imperative that the content of mother-of-pearl powder in these products should be very limited in order to avoid these irritation phenomena. These undesirable phenomena of irritation are in particular caused by the pH, which is too basic, of these known products, in contact with the skin.
  • the known products based on mother-of-pearl powder have specific formulation problems, in particular stability (breaking of emulsions) and of adjustment of the pH to a less basic value.
  • application WO 97/24133 describes a method for preparing biologically active substances from mother-of-pearl, by bringing a mother-of-pearl powder into contact with an aqueous solvent chosen from pure, double-distilled or apyrogenic water, optionally supplemented with salts, from which the water-soluble fraction is then separated so as to recover only the aqueous fraction, therefore essentially lacking the water-insoluble organic phase and inorganic components of mother-of-pearl.
  • This method cannot therefore enable, in particular, the preparation of a composition comprising in particular all of the components of mother-of-pearl, particularly the entire organic phase of mother-of-pearl.
  • a subject of the present invention is thus a method for preparing a composition, characterized in that it comprises the steps consisting:
  • the present method makes it possible to obtain a composition in the form of the extraction mixture obtained in step b).
  • the mother-of-pearl used for the implementation of the method according to the invention may be obtained from shells of nacreous mollusks and of some cephalopods, for example nautilus). In particular, it is obtained from oysters, such as Pinctada maxima.
  • Raw mother-of-pearl is used, which is free of other polysaccharide- and calcite-rich shell elements.
  • the starting material is preferably white mother-of-pearl, otherwise it is necessary to provide a step for removing the pigments which may cause intolerance.
  • an additional advantage comes from the fact that the raw material can be obtained from oyster shells which have produced pearls; specifically, a pearl oyster is removed from the productive pool after having produced at most three pearls in succession, although it has a thick layer of mother-of-pearl of excellent quality (grade A).
  • the present invention therefore provides an extra opportunity for using mother-of-pearl downstream of pearl farming.
  • the particle size of the mother-of-pearl powder used for carrying out the present method is between approximately 1 and approximately 300 ⁇ m, as measured with conventional means within the scope of those skilled in the art, such as the sieving technique and/or the LASER-reading technique.
  • the mother-of-pearl is reduced to a powder with a particle size of between approximately 50 and approximately 100 ⁇ m.
  • the mother-of-pearl is reduced to a powder with a particle size of between approximately 15 and approximately 50 ⁇ m, which makes it possible to improve the yield by approaching the size of a crystalline unit (for example, the elemental unit of mother-of-pearl from Pinctada maxima is the biocrystal, a very voluminous hexagonal crystal of aragonite of 9 to 12 ⁇ m).
  • a crystalline unit for example, the elemental unit of mother-of-pearl from Pinctada maxima is the biocrystal, a very voluminous hexagonal crystal of aragonite of 9 to 12 ⁇ m.
  • the outer part of the shell (periostracum) is removed from the raw mother-of-pearl by grinding or any other nondenaturing method.
  • the sheets of mother-of-pearl are then reduced to fragments by crushing so as to then be able to perform micronization.
  • the fragments intended to be micronized are preferably between approximately 2 and approximately 5 centimeters in length and are approximately 0.3 centimeters thick.
  • the fragments are micronized.
  • the mother-of-pearl can be used without prior decontamination.
  • a very rapid decontaminating wash is performed, without soaking the fragments, in a solution of sodium hypochlorite at 6.6% of active chlorine (12°). Drying must be carried out extemporaneously so as to remove all traces of water.
  • the grinding must be done dry in zirconium jars reserved exclusively for this purpose, washed (water containing bleach, rinse, then wash with distilled water) and hot-sterilized beforehand. The crushing is carried out with zirconium balls, themselves sterilized.
  • the raw mother-of-pearl reduced to powder can be sterilized in two different ways:
  • Step b) of the method according to the invention consists in bringing the mother-of-pearl powder described above into close contact with an extracting agent in the form of an aqueous-glycolic solution of at least one collagen, of at least one proteoglycan or of a mixture thereof.
  • aqueous-glycolic solution is intended to mean a solution of the collagen and the proteoglycan obtained using an aqueous-glycolic solvent, i.e., in general, a solvent in the form of a mixture of water and at least one glycol.
  • glycol is intended to mean, in a known manner, any compound having two alcohol functions.
  • the glycol which may be used is chosen from the group consisting of ethylene glycol, propylene glycol, butylene glycol and mixtures thereof.
  • the water which may be used to form the aqueous-glycolic solvent may be pure, double-distilled, apyrogenic or demineralized water, or else deionized water.
  • the water:glycol weight ratio in the aqueous-glycolic solvent is preferably between approximately 1:100 and approximately 100:1, and more particularly between approximately 1:1 and approximately 20:1.
  • the extracting agent is preferably an aqueous-glycolic solution of at least one collagen.
  • the collagen which may be used in aqueous-glycolic solution in the extracting agent according to the invention may be any collagen constituting the intracellular substance of the connective tissue, available in the animal kingdom, known to those skilled in the art.
  • marine collagen i.e. a collagen derived from an organism of marine origin, such as marine vertebrates.
  • marine collagen is the main constituent of the connective tissues of fish, in which it fulfills an essential role in the structure of the skin, muscles, tendons and ligaments.
  • a collagen concentration is used which is between approximately 0.0001 and approximately 50% by weight, and more particularly between approximately 0.01 and approximately 15% by weight, relative to the total weight of the extracting agent.
  • the extracting agent is also preferably an aqueous-glycolic solution of at least one proteoglycan.
  • the proteoglycan which may be used in aqueous-glycolic solution in the extracting agent according to the invention may be any proteoglycan known to those skilled in the art, in particular any proteoglycan not containing sulfur.
  • the proteoglycan is chosen from the group consisting of hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate and mixtures thereof.
  • Hyaluronic acid is most particularly preferred, such as that marketed by the company Laboratoire Industriel de Biologie (Soisy Sous Montmorency, France).
  • the proteoglycan concentration used is preferably between approximately 0.0001 and approximately 40% by weight, and more particularly between approximately 0.01 and approximately 10% by weight, relative to the total weight of the extracting agent.
  • the extracting agent may also comprise any additional compound known to those skilled in the art, which is suitable f or the extraction step itself or in view of the possible uses of the composition prepared by the present method, such as those described hereafter.
  • the extracting agent may thus, for example, also comprise complexing agents, such as EDTA (ethylenediaminetetraacetic acid).
  • the mother-of-pearl powder is brought into close contact with the extracting agent according to step b) by preparing a mixture, consisting of the mother-of-pearl powder and the extracting agent, such that it comprises, relative to its total weight, approximately 20 to approximately 60% by weight of mother-of-pearl powder obtained in step a), as described above, and the remainder as extracting agent as described above.
  • the mother-of-pearl powder can be brought into close contact with the extracting agent, according to step b) of the present method, in particular by suspending the mother-of-pearl powder in the extracting agent, with vigorous and homogeneous mechanical stirring, so as to allow an extraction coating of the mother-of-pearl particles.
  • the procedure may, for example, be carried out at ambient temperature, i.e. at a temperature of about 20° C. for approximately 1 hour, but the durations and temperatures may be adjusted, by those skilled in the art, in particular depending on the starting particle size of the mother-of-pearl powder.
  • step b) for bringing about contact may be carried out by passing the extracting agent, under pressure, through the mother-of-pearl powder, which has been immobilized.
  • This immobilization may, for example, be effected using a column, of the HPLC type, optionally in a mixture with fillers which allow better diffusion of the extracting agent and avoid compaction of the mother-of-pearl powder.
  • the close contact is preferably brought about, for a given temperature, for a period of time sufficient to produce a virtually complete extraction.
  • the term “virtually complete extraction” is intended to mean the extraction of all the extractable components from the mother-of-pearl when it is brought into contact with the extracting agent.
  • the step for bringing about contact may comprise, before it ends, a period during which the suspension of the mother-of-pearl powder in the extracting agent is left to stand (stirring arrested).
  • step b) for bringing about contact the extraction mixture, formed as a result of the bringing into close contact, which constitutes the desired composition, is recovered.
  • composition in the form of an aqueous-glycolic suspension, may be stored as it is before use. For practical reasons of subsequent implementation (storage, transport, formulation, etc.) it is also possible to separate the liquid phase of this composition from the solid phase.
  • the method according to the invention is characterized in that, at the end of step b), the extraction mixture, formed as a result of the bringing into close contact, which constitutes the desired composition, is recovered and the liquid phase of the composition is separated from the solid phase by means known to those skilled in the art, such as ultra-filtration means, tangential filtration means, etc.
  • a subject of the present invention is also a novel composition which can be obtained using the method as described above (comprising the solid and liquid phases, with or without a separation step as described above).
  • this composition is characterized in that it comprises at least, in the form of an aqueous-glycolic suspension of a liquid phase and of a solid phase:
  • the expressions “collagen not derived from mother-of-pearl” and “proteoglycan not derived from mother-of-pearl” are intended to mean, respectively, the collagen and the proteoglycan used for the extracting agent of step b) of the present method.
  • the expression “aqueous-glycolic suspension” is explained by the fact that the composition according to the invention comprises not only soluble components (in aqueous-glycolic solution) but also insoluble components (in particular aragonite).
  • the collagen not derived from mother-of-pearl in the composition according to the invention is preferably a marine collagen, and more particularly a marine collagen chosen from the group consisting of “PANCOGENE R MARIN”, “COLLAGENE NATIF MARIN—Code 690” and mixtures thereof.
  • the proteoglycan not derived from mother-of-pearl may be any proteoglycan known to those skilled in the art, in particular any proteoglycan not containing sulfur, and is in particular chosen from the group consisting of hyaluronic acid, chondroitin sulfate, dermatan sulfate, eparan sulfate, keratan sulfate and mixtures thereof, and is more particularly hyaluronic acid.
  • this composition has properties which are very advantageous with respect to the skin and/or superficial body growths, in particular tissue-regenerating properties, allowing for example improved wound healing, and anti-aging properties making it possible to prevent and/or visibly decrease the effects related to aging of the skin and/or superficial body growths.
  • tissue-regenerating properties allowing for example improved wound healing, and anti-aging properties making it possible to prevent and/or visibly decrease the effects related to aging of the skin and/or superficial body growths.
  • Its action on the various cell types of the skin is one of repair and of regulation of the physiological balance between its various constituents. More particularly, its organic and inorganic components act in particular, at several levels, on keratinocyte metabolism.
  • This composition allows restructuring of the epidermis, contributing to better protection of the deepest layers. The epidermis becomes more resistant and deeper and interacts continually with the dermis. In addition, this composition allows enrichment in elastin and collagens.
  • the skin is more elastic and firmer. It is resistant and its components are renewed at a sustained rhythm.
  • this composition stabilizes synthesis of pigments and promotes microcirculation.
  • this composition has the advantage of being totally innocuous and that of having an anti-inflammatory, and therefore soothing, effect.
  • a subject of the present invention is also a pharmaceutical composition, characterized in that it comprises, as active principle, the novel composition as described above, which can be obtained using the method according to the invention, and a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is preferably an excipient suitable for dermatological application.
  • a subject of the present invention is also the use of this novel composition as described above, which can be obtained using the method as described above, for producing a medicinal product intended for the treatment of tissue regeneration disorders of the skin and/or superficial body growths.
  • a subject of the present invention is the use of the novel composition as described above, which can be obtained using the method as described above, for producing a medicinal product intended for the treat-ment of disorders of the skin and/or superficial body growths related to aging.
  • a subject of the present invention is the use of the novel composition as described above, which can be obtained using the method as described above, for producing a medicinal product intended for the treat-ment of inflammatory skin manifestations.
  • a subject of the present invention is also a cosmetic composition, characterized in that it comprises, as cosmetically active principle, the novel composition as described above, which can be obtained using the method according to the invention, and a cosmetically acceptable excipient.
  • the cosmetic composition according to the invention may also contain ingredients of the cosmetic type, known to those skilled in the art, such as moisturizers, softeners, or chemical or organic screening agents.
  • compositions described above may, in particular, be in the form of a cream, an ointment, a gel, a lotion, an oil-in-water emulsion or a water-in-oil emulsion, or may be combined with any pharmaceutically or cosmetically acceptable vector, such as liposomes.
  • a subject of the present invention is the use of the novel composition as described above, which can be obtained using the method according to the invention, for producing a cosmetic composition intended for cosmetic treatment for tissue regeneration of the skin and/or superficial body growths.
  • a subject of the present invention is the use of the novel composition as described above, which can be obtained using the method according to the invention, for producing a cosmetic composition intended for the cosmetic treatment of modifications related to aging of the skin and/or superficial body growths.
  • a subject of the present invention is a method of cosmetic treatment for tissue regeneration of the skin and/or superficial body growths, characterized in that the novel composition as described above, which can be obtained using the method according to the invention, is applied to the skin and/or superficial body growths.
  • a subject of the present invention is a method of cosmetic treatment of modifications related to aging of the skin and/or superficial body growths, characterized in that the novel composition as described above, which can be obtained using the method according to the invention, is applied to the skin and/or superficial body growths.
  • FIGS. 1 and 2 represent a Western blot of a composition prepared using the method according to the invention.
  • FIG. 3 represents a histogram of the overall amino acid composition of the protein phase of the composition prepared using the method according to the invention.
  • FIGS. 4 and 5 are photographs illustrating the effect of the composition prepared according to the invention on cytokeratin synthesis by human keratinocytes.
  • FIGS. 6 and 7 are photographs illustrating the effect of the composition prepared according to the invention on human keratinocytes in culture subjected to estradiol withdrawal.
  • FIGS. 8 and 9 are photographs illustrating the effect of the composition prepared according to the invention con cytokeratin synthesis by human keratinocytes in culture subjected to estradiol withdrawal.
  • FIGS. 10 and 11 are photographs illustrating the effect of the composition prepared according to the invention on elastin synthesis by human fibroblasts.
  • FIGS. 12 and 13 are photographs illustrating the effect of estrogens on human fibroblasts.
  • FIGS. 14 and 15 are photographs illustrating the effect of the composition prepared according to the invention on human fibroblasts subjected to estradiol withdrawal.
  • FIG. 16 is a histogram illustrating the effect of the composition prepared according to the invention on melanocytes, through the modification of the amount of melanin taken up by keratinocytes cultured in the presence of the composition.
  • FIGS. 17 and 18 are photographs illustrating the effect of the composition prepared according to the invention on the amount of melanin taken up by cultured human keratinocytes.
  • FIG. 19 is a histogram illustrating the effect of the composition prepared according to the invention on interleukin 1 (IL-1) secretion by HL 60 promyelocytic cells.
  • IL-1 interleukin 1
  • FIG. 20 is a histogram illustrating the study of the noncytotoxicity of the composition prepared according to the invention.
  • the material used should be a material of the type under vacuum, completely airtight, and preferably made of stainless steel. It should be washed and rinsed cleanly beforehand so as to avoid any risk of bacterial contamination.
  • the fragments are given a very rapid decontaminating wash, without soaking, in a solution of sodium hypochlorite at 6.6% of active chlorine (12°) and are then dried extemporaneously in order to remove any trace of water.
  • the grinding for the micronization must be carried out dry in zirconium jars reserved exclusively for this purpose, washed (water containing bleach+rinse+distilled water wash) and hot-sterilized beforehand. The grinding is carried out using zirconium balls, which are themselves sterilized.
  • the micronized mother-of-pearl powder thus obtained has a particle size of between 50 and 150 ⁇ m. It is then sterilized by irradiation with ⁇ -rays, 2.5 Mrad.
  • the mixture is then left to stand for 6 hours.
  • composition thus obtained is composed of an off-white particulate solid phase, in suspension in a liquid phase and at a pH of approximately 8.
  • This composition comprises:
  • FIGS. 1 and 2 The corresponding Western blots are represented in FIGS. 1 and 2 .
  • the amino acid analysis of the protein phase indicates the presence of aspartic acid, threonine, serine, glutamic acid, glycine, alanine, proline, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine.
  • FIG. 3 represents a histogram of the overall amino acid composition.
  • composition A The composition obtained as described above will be named hereafter “composition A”.
  • composition A Activity of Composition A on Keratinocytes: Cytokeratin Synthesis by Human Keratinocytes Cultured in the Presence of Composition A
  • Keratinocytes are the outermost cells of our body. They constitute our first protective barrier. Keratinocytes intervene by acting passively and actively. They produce the passive protection by constituting a barrier which plays the role of a shield. This shield is made from cells which are dried-out and anucleated. The strong cohesion of the cells makes it possible to provide a very homogeneous system. Keratinocytes synthesize substances, cytokeratins, which they maintain in their cytoplasm in order to give this barrier structure. The cytokeratins constitute the internal skeleton of keratinocytes. This internal skeleton gives these cells their volume and increases their capacity for intercellular communication and facilitates melanin uptake.
  • cytokeratins The richer the epidermis is in cytokeratins, the more effective it is and the more it gives the skin its young appearance. By facilitating contact between the cells, the cytokeratins prevent loss of the NMS (Natural Moisturizing Factors, such as ceramides, cholesterol or fatty acids).
  • NMS Natural Moisturizing Factors, such as ceramides, cholesterol or fatty acids.
  • keratinocytes are the first cells of our body to be in contact with the outside. They have therefore developed a panoply of components intended to inform our body of possible changes in the conditions of our environment. To do this, these cells are capable of synthesizing growth factors intended to stimulate the cells subjacent to the dermis (fibroblasts), in particular PTH related peptide (PTHrp), which is synthesized mainly by keratinocytes and known to be a cellular differentiation factor.
  • PTHrp PTH related peptide
  • the method used was as follows. It includes a rapid semiquantitative technique which makes it possible to assess the level of each of the secreted proteins present in the cell cytoplasm.
  • the cultures are incubated for 48 h. After the supernatants have been removed and the Cultures rinsed, the cells are fixed with paraformaldehyde for 30 min at 40° and then rinsed with PBS buffer.
  • the amount of proteins, in this instance of cytokeratins, synthesized by the cells and thus labeled is proportional to the strength of the fluorescence resulting from the immunolabeling.
  • composition A restores the activity of keratinocytes from old skin and also the secretion of cytokeratin by these keratinocytes (action on keratinocytes subject to estradiol withdrawal; see FIGS. 6 , 7 and 8 , 9 ).
  • composition A calcium-dependent PTHrp synthesis by the keratinocytes is stimulated in the presence of composition A.
  • the PTHrp synthesized mainly by the keratinocytes, is particularly active in the presence of the calcium ion provided by composition A and acts synergistically with the cytokines of the complete organic matrix of the mother-of-pearl present in composition A.
  • Cadherins calcium-dependent adhesion proteins, are also largely responsible for cohesion. They are stimulated in the presence of composition A.
  • composition A at a concentration of 1% strongly stimulates elastin synthesis by human fibroblasts.
  • Relatively inactive mature fibroblasts are very elongated and flat in shape and have dense nuclei. Active fibroblasts have nuclei which are large in size and rounded, with voluminous nucleoli, reflecting the active process of synthesis.
  • the “active fibroblast” type is observed in the cultures of skin explants taken from a 50-year-old woman undergoing hormone replacement therapy.
  • Estrogen deprivation in the culture medium causes drastic inactivation of the cells. They are no longer adherent nor confluent, and some exhibit the beginning of pyknosis.
  • FIGS. 12 and 14 illustrate the effect of composition A on human fibroblasts from explants from 50-year-old menopausal (therefore with decreased estrogen secretion) women undergoing replacement therapy.
  • FIGS. 13 and 15 illustrate the effect of composition A on human fibroblasts subjected to estradiol withdrawal, from explants from 50-year-old menopausal women undergoing replacement therapy.
  • composition A added to the culture medium at 1%, completely restores the activity of the fibroblasts having been subjected to the withdrawal.
  • the action of composition A is notable: fibroblasts have a well-developed, very clear nucleus with a prominent nucleolus. Their fusiform cell bodies line up in the same direction and are confluent, allowing cellular exchanges. Similar results were obtained when working on cells from explants of young skin.
  • Melanocytes are the pigmentary cells responsible for melanin synthesis, melanin being the pigment which causes skin color. Melanocytic cells represent approximately 2 to 4% of the total epidermal population. The homogeneous color of the skin is due to distribution of the pigment over the entire surface of the skin by virtue of melanin transfer, in the form of melanosomes, from the secretory cells (melanocytes) to the neighboring keratinocytes which take it up.
  • the method consists in preparing a keratinocyte/melanocyte coculture and assaying melanin.
  • Keratinocytes and melanocytes are both cell populations located in the epidermis. They are obtained from a skin sample after removal of the dermis and enzymatic digestion of the epidermis. The epidermal cells thus isolated are counted in a Coulter Counter (Coultronics) and are then cultured in a conventional culture medium of the medical Dulbeco type (eagle medium) supplemented with glutamine, streptomycin/penicillin and 10 of fetal calf serum. The percentages are adjusted as a function of the results obtained. This medium allows survival of melanocytes and keratinocytes.
  • composition A After incubation for 4 days in the presence of composition A, the cells are digested with an NaOH/DMSO mixture and the supernatant is then recovered after centrifugation. Reading is performed at 470 nm.
  • composition A causes a significant change in distribution of the melanin taken up by the keratinocytes, avoiding localized concentrations (see FIGS. 17 and 18 ).
  • the incubation lasts 30 minutes at room temperature.
  • the supernatants are then removed and the cells are rinsed with PBS.
  • 200 ⁇ l of the second antibody conjugated to fluorescein are added.
  • the supernatants are removed and the cells are rinsed with PBS.
  • the slides are then mounted, followed by examination under an inverted fluorescence microscope. The amounts of elastin or of cytokeratin synthesized by the cells are proportional to the strength of the fluorescence.
  • composition A The addition of 1% of composition A to the keratinocyte culture medium has the effect of increasing cytokeratin synthesis by the keratinocyte cells of the epidermis. This stimulation is observed considerably from 0.5% of composition A.
  • composition A (at 1%) a very noticeable increase in the strength of the fluorescence is observed, after 48 hours, thus reflecting stimulation of elastin synthesis by the fibroblasts of the dermis.
  • Composition A Assaying of Interleukin 1 (Il-1) Secreted by HL 60 Promyelocytic Cells Treated with Composition A
  • IL-1 secretion is measured using a cell line, HL-60, in the presence of composition A.
  • IL-1 The production of IL-1 is amplified by adding phytohemaglutinin (PHA), which is a powerful stimulant of IL-1 secretion, to the culture medium.
  • PHA phytohemaglutinin
  • the IL-1 is quantified via the conventional technique of immunoassay by ELISA using a specific antibody directed against human IL-1.
  • composition A on the production of interleukin 1 (IL-1, in picograms) secreted by the promyelocytic cells Standard
  • Sample 1 Sample 2
  • Sample 3 Mean deviation Control 0.703 0.685 0.654 0.681 0.025
  • Composition A 0.494 0.615 0.527 0.545 0.063 (0.5%)
  • composition A In the presence of 1% of composition A, a significant decrease in IL-1 synthesis is therefore observed, thus reflecting a very notable anti-inflammatory effect of composition A. This in vitro effect was also observed when implantation was performed in rats in vivo.
  • MTT tetrazolium salt
  • composition A in the culture medium therefore leads to a considerable increase in the cellular mitochondrial activity.
  • This stimulation of the enzymatic activity is dose-dependent: the higher the concentration of composition A, the higher the activity.
  • the mitochondrial activity of the cells is greatly superior to that of the control cells not treated with composition A.
  • Composition A acts directly on the most superficial layers of the epidermis.
  • the organic and inorganic components of the extract express themselves at several levels in keratinocyte metabolism by acting on the activity of the cells of the basal layer.
  • the differentiation sequence for basal keratinocytes which are star-shaped and then granular, is stimulated and controlled without any increase in the number of cells.
  • the controlled increase in the number of keratinocytes improves the structure of the epidermis and the dermal-epidermal junctions.
  • the restructuring of the epidermis contributes to better protection of the deepest layers.
  • the improvement in specific syntheses such as those of the cytokeratins, stabilizes pigment syntheses and ensures a physiological repartition of the melanin within the keratinocytes, resulting in the lack of localized concentrations.
  • the improvement in the protection of the skin occurs without inducing any abnormal thickening of the skin, while at the same time deepening the sheets of cells layered on the dermal-epidermal junction.
  • Substances which contribute to improving the response of cells to attack and to inflammation, and also the communication factors which allow physiological exchanges between the epidermis and dermis, are found among the set of mediators secreted by the keratinocytes.
  • the cellular renewal of the epidermis which is 4 to 6 weeks, is maintained at its physiological rhythm.
  • Amplification of mediator synthesis increases the recruitment of an entire set of cells, and the decorin provided by composition A at the epidermal level is included among these mediators.
  • composition A acts on the growth and differentiation of keratinocytes. This effect is calcium-dependent, hence the advantage of the presence of the ionized calcium in composition A.
  • the stimulation cascade produced by the local mediators released in the epidermis causes the synthesis of a very abundant extracellular matrix by the fibroblasts. This is very structured. It is in particular composed of proteoglycans, of collagen and of adhesion proteins, in particular of decorin, an adhesion protein which plays a major role in the phenomena of restructuring of the skin (or skin tissue regeneration). It traps cytokines and other growth factors. These observations were also noted in viva in rats.
  • composition A the fibers of which exhibit better orientation in the connective layer, allow skin tissues to keep their suppleness and their shape during the physiological degradations caused either by deficiencies and age, or by attacks, in particular stretching.
  • Turgescent fibroblasts are recruited to the precursor stem cells in sufficient number for the effect due to their action and presence to be long-lasting. This effect is maintained by an increased microvascularization.
  • the skin is more elastic and firmer. It is resistant. Its components are renewed at a sustained rhythm.
  • composition A on the various cell types of the skin is one of repair and regulation of the physiological balance between the various constituents.
  • it has the advantage of being totally innocuous and that of having an anti-inflammatory, and therefore soothing, effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/089,982 1999-10-05 2000-10-05 Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology Expired - Fee Related US6936280B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9912409A FR2799125B1 (fr) 1999-10-05 1999-10-05 Procede de preparation d'une composition par extraction de nacre, comprenant l'integralite des composants de la nacre, composition obtenue par ce procede et son utilisation en pharmacie et cosmetique.
PCT/FR2000/002766 WO2001024804A2 (fr) 1999-10-05 2000-10-05 Procede de preparation d'une composition par extraction de nacre et son utilisation en cosmetique et dermatologie

Publications (1)

Publication Number Publication Date
US6936280B1 true US6936280B1 (en) 2005-08-30

Family

ID=9550589

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/089,982 Expired - Fee Related US6936280B1 (en) 1999-10-05 2000-10-05 Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology

Country Status (11)

Country Link
US (1) US6936280B1 (fr)
EP (1) EP1221957B1 (fr)
JP (1) JP5047433B2 (fr)
KR (1) KR100822352B1 (fr)
AT (1) ATE327760T1 (fr)
AU (1) AU7794000A (fr)
CA (1) CA2386960C (fr)
DE (1) DE60028396T2 (fr)
ES (1) ES2267572T3 (fr)
FR (1) FR2799125B1 (fr)
WO (1) WO2001024804A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275231A1 (en) * 2005-05-10 2006-12-07 L'oreal Cosmetic composition, a packaging device and a method of application
US20080268070A1 (en) * 2005-02-10 2008-10-30 Kabushiki Kaisha Asadasyokai Skin Care Cream Containing Baked Shell Powder and Method of Manufacturing the Same
US8205623B2 (en) * 2010-04-05 2012-06-26 Rovcal, Inc. Coatings for personal grooming apparatus containing calcium carbonate derived from mollusk shells or pearls
TWI398256B (zh) * 2005-09-05 2013-06-11 Asadasyokai Kk Cream coated with shellfish and its manufacturing method
CN107771087A (zh) * 2015-06-23 2018-03-06 Mbp(毛里求斯)有限公司 通过改性天然海洋生物材料组合物获得的半合成粉末材料，其制备方法及其应用
US20190290575A1 (en) 2018-03-23 2019-09-26 Mary Kay Inc. Topical compositions and methods
CN110624097A (zh) * 2019-08-30 2019-12-31 广东海洋大学 一种珍珠贝小分子肽在皮肤创伤修复中的应用
CN112877389A (zh) * 2021-01-20 2021-06-01 广州市尚梓化工科技有限公司 一种珍珠亮白肽的制备方法及在美白化妆品中的应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004083451A (ja) * 2002-08-26 2004-03-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
FR2850574B1 (fr) * 2003-02-04 2007-04-20 Robert Wan Holding Composition cosmetique regenerante et procede d'extraction de lipides a partir de mollusques nacriers
JP4081408B2 (ja) * 2003-06-06 2008-04-23 株式会社ナリス化粧品 皮膚外用剤
FR2856303B1 (fr) * 2003-06-20 2007-09-07 Innovation Et De Rech Applique Utilisation therapeutique de lipides extraits de nacre
FR2863163B1 (fr) * 2003-12-04 2006-02-24 Oreal Composition, notamment cosmetique, comprenant des extraits de fougere et de nacre
JP4303616B2 (ja) * 2004-03-01 2009-07-29 花王株式会社 メラノソーム転送の検出法
DE102004046686A1 (de) * 2004-09-24 2006-04-06 Henkel Kgaa Perlenextrakt in kosmetischen Mitteln
JP2008526771A (ja) * 2004-12-30 2008-07-24 ジェンザイム コーポレーション 高リン酸血症のための亜鉛含有処置
FR2880277B1 (fr) * 2005-01-04 2007-04-06 Georges Camprasse Preparations a usage orthopedique et dermatologique, destinees aux equides, bovides et autres animaux domestiques a base de biopolymeres marins, solubles et insolubles, et de biocritaux d'aragonite
FR2885520B1 (fr) * 2005-05-10 2007-10-05 Oreal Composition cosmetique
CA2620406A1 (fr) 2005-09-02 2007-03-08 Genzyme Corporation Recepteurs moleculaires polymeriques utilises comme sequestrants du phosphate
KR101324578B1 (ko) * 2006-02-03 2013-11-01 제이알 켐, 엘엘씨 구리 및 아연 조성물을 사용하는 노화 방지 치료법
FR2899478A1 (fr) * 2006-04-05 2007-10-12 Innovation Et De Rech Applique Procede d'extraction de molecules de nacre, compositions et utilisation
FR2922105B3 (fr) * 2007-10-10 2009-09-11 Mundema Preparation d'un complexe a base de calcium conchylien et produits ainsi obtenus, utiles notamment en cosmetologie, dermatologie et nutraceutique
JP2009209093A (ja) * 2008-03-04 2009-09-17 Shiseido Co Ltd 皮膚バリアー機能回復促進剤及び皮膚外用剤
JP5219038B2 (ja) * 2008-10-28 2013-06-26 学校法人順天堂 皮膚角化促進剤
FR2944214B1 (fr) * 2009-04-10 2012-04-27 Centre Nat Rech Scient Obtention et utilisation de principe actifs des calcaires
FR2946885B1 (fr) * 2009-06-17 2011-08-26 Phagexel Composition de nacre destinee a corriger des defauts de nidation chez les mammiferes.
FR2946883B1 (fr) * 2009-06-22 2012-04-13 Newco Brevets Produit et procede pour ameliorer la fertilite des mammiferes
JP5679402B2 (ja) * 2010-02-08 2015-03-04 御木本製薬株式会社 皮膚角化促進剤
FR3062302B1 (fr) * 2017-02-01 2020-12-04 Cosmoluxury Nouvelle composition cosmetique comprenant de la nacre ou un extrait de nacre

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10236941A (ja) * 1997-02-21 1998-09-08 Noevir Co Ltd 皮膚外用剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743075B1 (fr) * 1995-12-28 1998-03-27 Centre Nat Rech Scient Procede de preparation de substances actives a partir de la nacre, produits obtenus, utiles notamment comme medicaments
ES2220257T1 (es) * 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10236941A (ja) * 1997-02-21 1998-09-08 Noevir Co Ltd 皮膚外用剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lopez et al Tissue & Cell (1992), 24(5): 667-679. Demonstration of the capacity of nacre to induce bone formation by human osteoblasts maintained in vitro. *
Silve et al. Calcified Tissue International (1992), 51(5): 636-369. Nacre initiates biomineralization by human osteoblasts maintained in vitro. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268070A1 (en) * 2005-02-10 2008-10-30 Kabushiki Kaisha Asadasyokai Skin Care Cream Containing Baked Shell Powder and Method of Manufacturing the Same
US20060275231A1 (en) * 2005-05-10 2006-12-07 L'oreal Cosmetic composition, a packaging device and a method of application
TWI398256B (zh) * 2005-09-05 2013-06-11 Asadasyokai Kk Cream coated with shellfish and its manufacturing method
US8205623B2 (en) * 2010-04-05 2012-06-26 Rovcal, Inc. Coatings for personal grooming apparatus containing calcium carbonate derived from mollusk shells or pearls
CN107771087A (zh) * 2015-06-23 2018-03-06 Mbp(毛里求斯)有限公司 通过改性天然海洋生物材料组合物获得的半合成粉末材料，其制备方法及其应用
CN107771087B (zh) * 2015-06-23 2021-04-23 Mbp(毛里求斯)有限公司 通过改性天然海洋生物材料组合物获得的半合成粉末材料，其制备方法及其应用
US20190290575A1 (en) 2018-03-23 2019-09-26 Mary Kay Inc. Topical compositions and methods
US11701322B2 (en) 2018-03-23 2023-07-18 Mary Kay Inc. Topical compositions and methods
CN110624097A (zh) * 2019-08-30 2019-12-31 广东海洋大学 一种珍珠贝小分子肽在皮肤创伤修复中的应用
CN112877389A (zh) * 2021-01-20 2021-06-01 广州市尚梓化工科技有限公司 一种珍珠亮白肽的制备方法及在美白化妆品中的应用

Also Published As

Publication number Publication date
AU7794000A (en) 2001-05-10
WO2001024804A2 (fr) 2001-04-12
EP1221957A2 (fr) 2002-07-17
KR100822352B1 (ko) 2008-04-16
WO2001024804A3 (fr) 2002-02-28
DE60028396T2 (de) 2007-04-12
FR2799125A1 (fr) 2001-04-06
ATE327760T1 (de) 2006-06-15
ES2267572T3 (es) 2007-03-16
CA2386960C (fr) 2011-08-16
JP5047433B2 (ja) 2012-10-10
EP1221957B1 (fr) 2006-05-31
KR20020047214A (ko) 2002-06-21
DE60028396D1 (de) 2006-07-06
CA2386960A1 (fr) 2001-04-12
JP2003510364A (ja) 2003-03-18
FR2799125B1 (fr) 2002-01-18

Similar Documents

Publication Publication Date Title
US6936280B1 (en) Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology
EP2566583B1 (fr) Procédé de préparation d'extrait de cellule d'oeuf de poisson
EP3459522B1 (fr) Utilisation d'extraits cellulaires pour le traitement des plaies
US7129218B2 (en) Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration
JPH0661262B2 (ja) 細胞増殖の刺激方法
JP2005336188A (ja) 化粧品及び皮膚科学におけるｌｉｆの使用
WO2024078588A1 (fr) Nouvelle utilisation de composé peptidique dans préparation de composition pour reconstruction du vieillissement de la peau
RU2195955C2 (ru) ПРИМЕНЕНИЕ БИЛОГИЧЕСКИ АКТИВНЫХ ВЕЩЕСТВ, ЭКСТРАГИРОВАННЫХ ИЗ РАСТЕНИЙ СЕМЕЙСТВА Dictyotacea ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИЙ, ПРЕДНАЗНАЧЕННЫХ ДЛЯ МОДИФИКАЦИИ СИНТЕЗА ГЛИКОЗИЛИРОВАННЫХ ЭЛЕМЕНТОВ ВНЕКЛЕТОЧНОЙ МАТРИЦЫ ТКАНЕЙ ЖИВОТНЫХ И ЧЕЛОВЕКА И КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ
KR101503158B1 (ko) 피부 주름 개선 및 탄력 증진용 화장료 조성물
CN105853341B (zh) 一种含有表皮干细胞分泌素的抗衰老护肤品及其制备方法
KR20090098705A (ko) 피부 노화 징후의 출현을 방지 또는 지연시키기 위한 활성제로서의 브라소카틀레야 마르셀라 코스 난초 추출물의용도
KR100490212B1 (ko) 피부 각질층의 아미노산 구성비율을 가지는 아미노산복합물과 그것을 함유한 노화방지 화장료 조성물
KR20210133391A (ko) 진주 추출에 의해 진주층의 모든 성분을 포함하는조성물이용하여 얻은 조성물,및 화장품 및 피부 의학에서의 이의 용도
JP2002526395A (ja) 化粧品あるいは皮膚科製品におけるボルド抽出物の使用
KR102439440B1 (ko) 산양유, 스피루리나 추출물 및 목단피 추출물을 함유하는 피부화장료 조성물 및 그 제조방법
KR20190113169A (ko) 피부 주름 개선, 보습, 항산화 및 염증 완화 효과가 증가된 진피, 후박, 현호색, 아선약의 에탄올 추출 조성물
AU619399B2 (en) Cosmetic composition containing compounds obtained by the culture of cells, especially fibroblasts or keratinocytes
KR101685921B1 (ko) 레페치니아 카울레센스 추출물의 미용 제제 및 미용 조성물
CN113876611A (zh) 唾液酸在制备促进胶原蛋白生成的制剂中的应用
KR20170096842A (ko) 불가사리로부터 피부 재생 인자 및 세포 성장 인자의 추출 방법 및 이의 응용
KR20240068867A (ko) 포피라334가 봉입된 세포외소포체의 용도
Singh et al. Snail extract for skin: A review of uses, projections, and limitations
RU2221545C1 (ru) Косметическое средство, улучшающее физиологическое состояние кожных покровов
KR20030086187A (ko) 천연물을 이용한 항노화 화장료
US20210315800A1 (en) Cosmetic or dermatological compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOPEZ, EVELYNE;CHEMOUNI, EDOUARD;REEL/FRAME:013027/0441

Effective date: 20020325

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20170830